Investments
619Portfolio Exits
112Funds
14Service Providers
1About ARCH Venture Partners
ARCH Venture Partners is a premier provider of seed and early stage venture capital for technology firms, with a special competence in co-founding and building firms from start-up. The firm's mission is to deliver promising technologies from the earliest stages to successful commercial application – from concept to commerce.
ARCH Venture Partners Headquarter Location
8755 W Higgins Road Suite 1025
Chicago, Illinois, 60631,
United States
773-380-6600
Expert Collections containing ARCH Venture Partners
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find ARCH Venture Partners in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
ARCH Venture Partners Web Traffic
ARCH Venture Partners Rank
Research containing ARCH Venture Partners
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned ARCH Venture Partners in 7 CB Insights research briefs, most recently on Feb 3, 2021.
Aug 4, 2020
Here Are Q2’s Most Active Healthcare Investors
Latest ARCH Venture Partners News
May 10, 2022
Pioneers in observing single molecules in living cells Funds will be used to build a product portfolio that harnesses the company’s innovative technology to unlock new possibilities in therapeutic and diagnostic development as well as basic life science research The company expands its management team and board of directors with the addition of several industry veterans January 20, 2022 03:00… The post ONI Closes $75 Million Series B Led by ARCH Venture Partners and Casdin Capital appeared first on Vertical Venture Partners.
ARCH Venture Partners Investments
619 Investments
ARCH Venture Partners has made 619 investments. Their latest investment was in Remix Therapeutics as part of their Series B on May 5, 2022.
ARCH Venture Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
5/17/2022 | Series B | Remix Therapeutics | $70M | No | 5 | |
5/9/2022 | Series B | Aspen Neuroscience | $147.5M | No | 4 | |
5/5/2022 | Unattributed VC | Vizgen | $85.2M | No | 1 | |
4/26/2022 | Series A | |||||
4/14/2022 | Series B |
Date | 5/17/2022 | 5/9/2022 | 5/5/2022 | 4/26/2022 | 4/14/2022 |
|---|---|---|---|---|---|
Round | Series B | Series B | Unattributed VC | Series A | Series B |
Company | Remix Therapeutics | Aspen Neuroscience | Vizgen | ||
Amount | $70M | $147.5M | $85.2M | ||
New? | No | No | No | ||
Co-Investors | |||||
Sources | 5 | 4 | 1 |
ARCH Venture Partners Portfolio Exits
112 Portfolio Exits
ARCH Venture Partners has 112 portfolio exits. Their latest portfolio exit was Aura Biosciences on October 29, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/29/2021 | IPO | 10 | |||
9/29/2021 | IPO | 2 | |||
8/11/2021 | Acquired | 2 | |||
Date | 10/29/2021 | 9/29/2021 | 8/11/2021 | ||
|---|---|---|---|---|---|
Exit | IPO | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 10 | 2 | 2 |
ARCH Venture Partners Acquisitions
1 Acquisition
ARCH Venture Partners acquired 1 company. Their latest acquisition was Caliper Life Sciences on May 01, 1998.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
5/1/1998 | Private Equity | $37.09M | Acquired |
Date | 5/1/1998 |
|---|---|
Investment Stage | Private Equity |
Companies | |
Valuation | |
Total Funding | $37.09M |
Note | Acquired |
Sources |
ARCH Venture Partners Fund History
14 Fund Histories
ARCH Venture Partners has 14 funds, including ARCH Venture Fund XI.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
1/28/2021 | ARCH Venture Fund XI | $1,850M | 2 | ||
10/28/2019 | ARCH Venture Fund X | Early-Stage Venture Capital | Open | $636M | 3 |
10/25/2019 | ARCH Venture Fund X Overage | $635.75M | 3 | ||
11/18/2016 | ARCH Venture Fund IX | ||||
8/27/2014 | ARCH Venture Fund VIII |
Closing Date | 1/28/2021 | 10/28/2019 | 10/25/2019 | 11/18/2016 | 8/27/2014 |
|---|---|---|---|---|---|
Fund | ARCH Venture Fund XI | ARCH Venture Fund X | ARCH Venture Fund X Overage | ARCH Venture Fund IX | ARCH Venture Fund VIII |
Fund Type | Early-Stage Venture Capital | ||||
Status | Open | ||||
Amount | $1,850M | $636M | $635.75M | ||
Sources | 2 | 3 | 3 |
ARCH Venture Partners Team
11 Team Members
ARCH Venture Partners has 11 team members, including current Founder, Managing Director, Keith L. Crandell.
Name | Work History | Title | Status |
|---|---|---|---|
Clinton W. Bybee | Founder | Current | |
Keith L. Crandell | Founder, Managing Director | Current | |
Robert Nelson | Founder | Current | |
Kristina Burow | Managing Director | Current | |
Steve Gillis | Managing Director | Current |
Name | Clinton W. Bybee | Keith L. Crandell | Robert Nelson | Kristina Burow | Steve Gillis |
|---|---|---|---|---|---|
Work History | |||||
Title | Founder | Founder, Managing Director | Founder | Managing Director | Managing Director |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.